Skip to Content

Generic Noxafil Availability

Noxafil is a brand name of posaconazole, approved by the FDA in the following formulation(s):

NOXAFIL (posaconazole - solution;iv (infusion))

  • Manufacturer: MERCK SHARP DOHME
    Approval date: March 13, 2014
    Strength(s): 300MG/16.7ML (18MG/ML) [RLD]

NOXAFIL (posaconazole - suspension;oral)

  • Manufacturer: SCHERING
    Approval date: September 15, 2006
    Strength(s): 40MG/ML [RLD]

NOXAFIL (posaconazole - tablet, delayed release;oral)

Has a generic version of Noxafil been approved?

No. There is currently no therapeutically equivalent version of Noxafil available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Noxafil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Tetrahydrofuran antifungals
    Patent 5,661,151
    Issued: August 26, 1997
    Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor M. & Lovey; Raymond G. & Pike; Russell E. & Wang; Haiyan & Liu; Yi-Tsung & Ganguly; Ashit K. & Bennett; Frank
    Assignee(s): Schering Corporation
    A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an ether or ester thereof (e.g., a polyether ester amino acid ester or phosphate ester) thereof or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
    Patent expiration dates:
    • July 19, 2019
      ✓ 
      Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 19, 2019
      ✓ 
      Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline antifungal polymorph
    Patent 6,958,337
    Issued: October 25, 2005
    Inventor(s): Andrews; David R. & Leong; William & Sudhakar; Anantha
    Assignee(s): Schering Corporation
    The crystalline polymorph Form I of (−)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I pharmaceutical compositions containing such a polymorph and methods of using such a polymorph to treat fungal infections in mammals are disclosed.
    Patent expiration dates:
    • October 5, 2018
      ✓ 
      Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Antifungal composition with enhanced bioavailability
    Patent 8,263,600
    Issued: September 11, 2012
    Inventor(s): Sharpe; Stefan & Sequeira; Joel & Harris; David & Mahashabde; Shashank
    Assignee(s): Merck Sharp & Dohme Corp.
    A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
    Patent expiration dates:
    • April 1, 2022
      ✓ 
      Drug product
  • Sulfoalkyl ether cyclodextrin compositions
    Patent 8,410,077
    Issued: April 2, 2013
    Assignee(s): CyDex Pharmaceuticals, Inc.
    SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
    Patent expiration dates:
    • March 13, 2029
      ✓ 
      Drug product
  • Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
    Patent 9,023,790
    Issued: May 5, 2015
    Assignee(s): Merck Sharp & Dohme Corp.
    The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
    Patent expiration dates:
    • July 4, 2031
      ✓ 
      Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
      ✓ 
      Drug product
  • Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
    Patent 9,358,297
    Issued: June 7, 2016
    Assignee(s): Merck Sharp & Dohme Corp.
    The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
    Patent expiration dates:
    • June 24, 2031
      ✓ 
      Patent use: PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide